Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...
Discusses Innovation Day With Focus on Corporate Updates, Growth Strategy and Product Demonstrations February 27, 2026 9:30 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果